Dusica Babovic-Vuksanovic MD FAAP, FACMG
Medical Genetics
Chair, Department of Medical Genetics, Mayo Clinic
Join to View Full Profile
200 1st StRochester, MN 55905
Phone+1 507-284-3215
Fax+1 507-284-1067
Dr. Babovic-Vuksanovic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Residency, Medical Genetics and Genomics, 1996 - 2000
University of Sarajevo FOMClass of 1981
Certifications & Licensure
AZ State Medical License 2016 - 2026
FL State Medical License 2016 - 2026
MN State Medical License 1997 - 2025
WI State Medical License 1999 - 2025
American Board of Pediatrics Pediatrics
American Board of Medical Genetics and Genomics Clinical Genetics and Genomics- American Board of Medical Genetics and Genomics Clinical Molecular Genetics and Genomics
Clinical Trials
- Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Start of enrollment: 2000 Sep 01
- Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 22
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Start of enrollment: 2020 Jun 20
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.Christopher L Moertel, Angela C Hirbe, Laura J Klesse, P Leia Nghiemphu, Dusica Babovic-Vuksanovic
Journal of Clinical Oncology. 2025-03-19 - 2 citationsReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2025-02-20 - Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing.Archis R Bhandarkar, Shaan Bhandarkar, Dusica Babovic-Vuksanovic, Aditya Raghunathan, Jonathan Schwartz
Journal of Neuro-Oncology. 2024-08-01
Press Mentions
Approved Drug May Be Repurposed to Treat Tumors Resulting from NF2-Related SchwannomatosisJune 21st, 2024
Professional Memberships
- American College of Medical GeneticsMember
- American Society of Human GeneticsFellow
- American Academy of PediatricsFellow
Other Languages
- Serbian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
